Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: M3814 100 mgDrug: M3814 200 mgDrug: M3814 300 mgDrug: M3814 400 mgDrug: M3814 50 mgRadiation: Fractionated RT
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 52
- Registration Number
- NCT02516813
- Locations
- 🇳🇴
Research site, Oslo, Norway
🇺🇸Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2020-08-03
- Target Recruit Count
- 792
- Registration Number
- NCT02395172
- Locations
- 🇺🇸
University of Alabama, Tuscaloosa, Alabama, United States
🇺🇸Mayo Clinic, Scottsdale , Phoenix, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
First in Human Study of M4344 in Participants With Advanced Solid Tumors
- Conditions
- Solid TumorAdvanced Solid Tumor
- Interventions
- Drug: M4344 40 mg BIWDrug: M4344 100 mg BIDDrug: M4344 150 mg QDDrug: M4344 350 mg QDDrug: M4344 10 mg BIWDrug: M4344 20 mg BIWDrug: M4344 160 mg BIWDrug: M4344 1200 mg BIWDrug: M4344 700 mg BIWDrug: M4344 80 mg BIWDrug: M4344 1050 mg BIWDrug: M4344 300 mg BIWDrug: M4344 450 mg BIWDrug: M4344 250 mg QDDrug: M4344 400 mgDrug: M4344 500 mg
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2023-03-16
- Target Recruit Count
- 97
- Registration Number
- NCT02278250
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
M6620 First in Human Study
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2020-04-01
- Target Recruit Count
- 200
- Registration Number
- NCT02157792
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
🇺🇸Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 204
- Registration Number
- NCT02155647
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute - West LA, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2020-07-13
- Target Recruit Count
- 549
- Registration Number
- NCT01919164
- Locations
- 🇷🇴
Research site, Bucharest, Romania
🇭🇰Research Site, Hong Kong, Hong Kong
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2021-12-20
- Target Recruit Count
- 1756
- Registration Number
- NCT01772004
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Scottsdale Healthcare Corporation, Scottsdale, Arizona, United States
🇺🇸Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
Oral Cladribine in Early Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2021-03-22
- Target Recruit Count
- 617
- Registration Number
- NCT00725985
- Locations
- 🇺🇸
Hope Research Institute Medical Plaza LLC Desert Hills, Phoenix, Arizona, United States
🇺🇸Multiple Sclerosis Center Drive, Neurology Suite 701, Newport Beach, California, United States
🇺🇸University of Colorado at Denver Health Sciences, Denver, Colorado, United States
CLARITY Extension Study
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2020-12-07
- Target Recruit Count
- 867
- Registration Number
- NCT00641537
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
🇷🇺Reseach Site, Saratov, Russian Federation
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-10-12
- Target Recruit Count
- 172
- Registration Number
- NCT00436826
- Locations
- 🇪🇸
Research Site, Seville, Spain
🇪🇸Research site, Barcelona, Spain